Literature DB >> 23921131

HDAC3 is essential for DNA replication in hematopoietic progenitor cells.

Alyssa R Summers1, Melissa A Fischer, Kristy R Stengel, Yue Zhao, Jonathan F Kaiser, Christina E Wells, Aubrey Hunt, Srividya Bhaskara, Jessica W Luzwick, Shilpa Sampathi, Xi Chen, Mary Ann Thompson, David Cortez, Scott W Hiebert.   

Abstract

Histone deacetylase 3 (HDAC3) contributes to the regulation of gene expression, chromatin structure, and genomic stability. Because HDAC3 associates with oncoproteins that drive leukemia and lymphoma, we engineered a conditional deletion allele in mice to explore the physiological roles of Hdac3 in hematopoiesis. We used the Vav-Cre transgenic allele to trigger recombination, which yielded a dramatic loss of lymphoid cells, hypocellular bone marrow, and mild anemia. Phenotypic and functional analysis suggested that Hdac3 was required for the formation of the earliest lymphoid progenitor cells in the marrow, but that the marrow contained 3-5 times more multipotent progenitor cells. Hdac3(-/-) stem cells were severely compromised in competitive bone marrow transplantation. In vitro, Hdac3(-/-) stem and progenitor cells failed to proliferate, and most cells remained undifferentiated. Moreover, one-third of the Hdac3(-/-) stem and progenitor cells were in S phase 2 hours after BrdU labeling in vivo, suggesting that these cells were impaired in transit through the S phase. DNA fiber-labeling experiments indicated that Hdac3 was required for efficient DNA replication in hematopoietic stem and progenitor cells. Thus, Hdac3 is required for the passage of hematopoietic stem/progenitor cells through the S phase, for stem cell functions, and for lymphopoiesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921131      PMCID: PMC3696547          DOI: 10.1172/JCI60806

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Hdac3 is essential for the maintenance of chromatin structure and genome stability.

Authors:  Srividya Bhaskara; Sarah K Knutson; Guochun Jiang; Mahesh B Chandrasekharan; Andrew J Wilson; Siyuan Zheng; Ashwini Yenamandra; Kimberly Locke; Jia-Ling Yuan; Alyssa R Bonine-Summers; Christina E Wells; Jonathan F Kaiser; M Kay Washington; Zhongming Zhao; Florence F Wagner; Zu-Wen Sun; Fen Xia; Edward B Holson; Dineo Khabele; Scott W Hiebert
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

2.  HDAC3 is a critical negative regulator of long-term memory formation.

Authors:  Susan C McQuown; Ruth M Barrett; Dina P Matheos; Rebecca J Post; George A Rogge; Theresa Alenghat; Shannon E Mullican; Steven Jones; James R Rusche; Mitchell A Lazar; Marcelo A Wood
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

3.  The specific role of histone deacetylase 2 in adult neurogenesis.

Authors:  Melanie Jawerka; Dilek Colak; Leda Dimou; Carmen Spiller; Sabine Lagger; Rusty L Montgomery; Eric N Olson; Wolfgang Wurst; Martin Göttlicher; Magdalena Götz
Journal:  Neuron Glia Biol       Date:  2010-04-14

Review 4.  Dynamics of epigenetic modifications in leukemia.

Authors:  Iris Uribesalgo; Luciano Di Croce
Journal:  Brief Funct Genomics       Date:  2011-01-21       Impact factor: 4.241

5.  Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.

Authors:  Chiara Conti; Elisabetta Leo; Gabriel S Eichler; Olivier Sordet; Melvenia M Martin; Angela Fan; Mirit I Aladjem; Yves Pommier
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

6.  Redundant control of adipogenesis by histone deacetylases 1 and 2.

Authors:  Michael Haberland; Michele Carrer; Mayssa H Mokalled; Rusty L Montgomery; Eric N Olson
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

7.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

Authors:  Sean J Whittaker; Marie-France Demierre; Ellen J Kim; Alain H Rook; Adam Lerner; Madeleine Duvic; Julia Scarisbrick; Sunil Reddy; Tadeusz Robak; Jürgen C Becker; Alexey Samtsov; William McCulloch; Youn H Kim
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism.

Authors:  Dan Feng; Tao Liu; Zheng Sun; Anne Bugge; Shannon E Mullican; Theresa Alenghat; X Shirley Liu; Mitchell A Lazar
Journal:  Science       Date:  2011-03-11       Impact factor: 47.728

9.  Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression.

Authors:  Teppei Yamaguchi; Fabien Cubizolles; Yu Zhang; Nina Reichert; Hubertus Kohler; Christian Seiser; Patrick Matthias
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

10.  Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.

Authors:  Jasmine Zain; Owen A O'Connor
Journal:  Invest New Drugs       Date:  2010-12-04       Impact factor: 3.850

View more
  42 in total

1.  NKAP Must Associate with HDAC3 to Regulate Hematopoietic Stem Cell Maintenance and Survival.

Authors:  Michael Jeremy Shapiro; Michael Jonathan Lehrke; Ji Young Chung; Sinibaldo Romero Arocha; Virginia Smith Shapiro
Journal:  J Immunol       Date:  2019-02-25       Impact factor: 5.422

2.  HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity.

Authors:  Wei-Kai Hua; Jing Qi; Qi Cai; Emily Carnahan; Maria Ayala Ramirez; Ling Li; Guido Marcucci; Ya-Huei Kuo
Journal:  Blood       Date:  2017-10-30       Impact factor: 22.113

3.  Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.

Authors:  Mitsuru Seki; Ryan LaCanna; Jeffery C Powers; Christine Vrakas; Fang Liu; Remus Berretta; Geena Chacko; John Holten; Pooja Jadiya; Tao Wang; Jeffery S Arkles; Joshua M Copper; Steven R Houser; Jianhe Huang; Vickas V Patel; Fabio A Recchia
Journal:  J Pharmacol Exp Ther       Date:  2016-06-27       Impact factor: 4.030

4.  FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3.

Authors:  Liqing Wang; Yujie Liu; Rongxiang Han; Ulf H Beier; Tricia R Bhatti; Tatiana Akimova; Mark I Greene; Scott W Hiebert; Wayne W Hancock
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

5.  HDAC3 Is Required for the Downregulation of RORγt during Thymocyte Positive Selection.

Authors:  Rachael L Philips; Meibo W Chen; Douglas C McWilliams; Paul J Belmonte; Megan M Constans; Virginia Smith Shapiro
Journal:  J Immunol       Date:  2016-06-08       Impact factor: 5.422

6.  Deacetylase activity of histone deacetylase 3 is required for productive VDJ recombination and B-cell development.

Authors:  Kristy R Stengel; Kelly R Barnett; Jing Wang; Qi Liu; Emily Hodges; Scott W Hiebert; Srividya Bhaskara
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

7.  Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.

Authors:  Ercument Dirice; Raymond W S Ng; Rachael Martinez; Jiang Hu; Florence F Wagner; Edward B Holson; Bridget K Wagner; Rohit N Kulkarni
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

8.  Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

Authors:  Jesse J McClure; Cheng Zhang; Elizabeth S Inks; Yuri K Peterson; Jiaying Li; C James Chou
Journal:  J Med Chem       Date:  2016-10-26       Impact factor: 7.446

9.  Histone Deacetylase 3 Is Required for Efficient T Cell Development.

Authors:  Kristy R Stengel; Yue Zhao; Nicholas J Klus; Jonathan F Kaiser; Laura E Gordy; Sebastian Joyce; Scott W Hiebert; Alyssa R Summers
Journal:  Mol Cell Biol       Date:  2015-08-31       Impact factor: 4.272

10.  BRPF1 is essential for development of fetal hematopoietic stem cells.

Authors:  Linya You; Lin Li; Jinfeng Zou; Kezhi Yan; Jad Belle; Anastasia Nijnik; Edwin Wang; Xiang-Jiao Yang
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.